Severe <scp>SARS‐CoV‐2</scp> infection in rituximab‐treated patients with autoimmune cytopenia: A multicenter observational study

Sorin, Boris; Gaigne, L.; Garzaro, Margaux; Moulis, Guillaume; Mageau, Arthur; Lopez, Catherine; Roy-Péaud, F.; Jeandel, Pierre-Yves; Crickx, Étienne; Dossier, Antoine; Gobert, Delphine; Hadjadj, Jérôme; Puyade, Mathieu; Languille, Laetitia; Rasmussen, Camille; Terrier, Benjamin; Ebbo, Mikaël; Bonnotte, B.; Audia, Sylvain; Galicier, Lionel; Michel, Marc; Mahévas, Matthieu; Viallard, Jean‐François; Godeau, Bertrand

doi:10.1002/ajh.27016

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study evaluated the incidence and risk factors associated with severe COVID-19 in a cohort of patients and demonstrated a low occurrence. Out of the 308 patients studied, only 11 had COVID-19 necessitating oxygen therapy, and only two died [ 34 ].…”

Section: Discussionmentioning

confidence: 99%

Cold Agglutinin Disease and COVID-19: A Scoping Review of Treatments and Outcomes

Musuuza,

Kumar,

Posa

et al. 2024

J Clin Med Res

View full text Add to dashboard Cite

Background Reports suggest that patients with both acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and cold agglutinin disease (CAD) may experience poorer survival when treated with rituximab. We conducted a scoping review to evaluate severe outcomes, including intensive care unit (ICU) admission and mortality, in coronavirus disease 2019 (COVID-19) patients with CAD on various treatments, including rituximab. Methods This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR). Four literature databases were searched on December 19, 2023, for studies reporting lab-confirmed SARS-CoV-2 and CAD, excluding rheumatological conditions. Results Of the 741 screened articles, 19 were included. Studies, predominantly case reports (17/19) or case series (2/19), were mainly from the USA (8/19) and India (3/19), with others across Europe and Asia. Among 23 patients (61% female, median age 61 years), 21/23 had a new CAD diagnosis; only two had pre-existing CAD. Overall, 74% recovered, 21% died, and outcomes for one were unreported. Nine (39%) were ICU-admitted. Of rituximab-treated patients (n = 4), 25% were ICU-admitted, none died. Non-rituximab treatments (n = 19) saw 42% ICU admissions and 26% mortality. Conclusions This review found no increased risk of severe outcomes in CAD and COVID-19 patients treated with rituximab.

show abstract

Section: Discussionmentioning

confidence: 99%